CDK4 and prostate carcinoma: Lastly, PF-07220060, a selective CDK4 inhibitor that spares CDK6, is being assessed in combination with enzalutamide in patients with prostate cancer in a phase 1/2a study whose primary outcome is safety (NCT04557449).